Open Access
Review
CBP/p300 bromodomain: new promising epigenetic target
Vis Cancer Med, 3 (2022) 3
Published online: 12 September 2022
Visualized Cancer Medicine
Visualized Cancer Medicine is an interdisciplinary and peer-reviewed journal, which publishes the advances in basic, translational, and clinical studies on cancer biology, cancer prevention, cancer screening and diagnosis, cancer treatments, and cancer patient rehabilitation, with an emphasis on videos presenting the natural process, interventional procedure, and spatial alteration of the studied objects.
Visualized Cancer Medicine is the official journal of the Society of Tumor Microenvironment, China Anti-Cancer Association.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
-
-
Open AccessEditorial
Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study
Vis Cancer Med, 3 (2022) E1Published online: 26 April 2022 -
Open AccessReview
MxA: a broadly acting effector of interferon-induced human innate immunity
Vis Cancer Med, 3 (2022) 2Published online: 06 April 2022 -
Open Access
An increase in early cancer detection rates at a single cancer center: Experiences from Sun Yat-sen University Cancer Center
Vis Cancer Med, 3 (2022) 1Published online: 01 March 2022 -
Open AccessReview
The innovation and clinical application of ischemia-free organ transplantation
Vis Cancer Med, 2 (2021) 6Published online: 01 December 2021 -
Open Access
Dosimetric comparison of intensity-modulated proton radiotherapy versus intensity-modulated photon-based radiotherapy for breast cancer
Vis Cancer Med, 2 (2021) 5Published online: 20 August 2021 -
Open AccessReview
Metastasis of nasopharyngeal carcinoma: What we know and do not know
Vis Cancer Med, 2 (2021) 4Published online: 11 August 2021 -
Open Access
ACE2 in tumor cells and tumor vasculature: Negligible intercellular transfer from cancer cells into endothelial cells
Vis Cancer Med, 2 (2021) 3Published online: 10 August 2021
| 31 |
Open Access
Review
CBP/p300 bromodomain: new promising epigenetic targetVis Cancer Med, 3 (2022) 3
Published online: 12 September 2022
|
| 16 |
Open Access
Clinical advances in nasopharyngeal carcinoma surgery and a video demonstrationVis Cancer Med, 2 (2021) 2
Published online: 22 April 2021
|
| 10 |
Open Access
ACE2 in tumor cells and tumor vasculature: Negligible intercellular transfer from cancer cells into endothelial cellsVis Cancer Med, 2 (2021) 3
Published online: 10 August 2021
|
| 9 |
Open Access
Review
MxA: a broadly acting effector of interferon-induced human innate immunityVis Cancer Med, 3 (2022) 2
Published online: 06 April 2022
|
| 6 |
Open Access
Review
Metastasis of nasopharyngeal carcinoma: What we know and do not knowVis Cancer Med, 2 (2021) 4
Published online: 11 August 2021
|
